Immutep Completes Patient Enrollment for Major Clinical Trial
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has successfully finalized the patient enrollment for its groundbreaking Phase II clinical trial known as EFTISARC-NEO. This important study is aimed at treating patients with soft tissue sarcoma (STS) through a combination of innovative therapies, incorporating eftilagimod alpha (efti), radiotherapy, and KEYTRUDA® (pembrolizumab).
About the EFTISARC-NEO Trial
The EFTISARC-NEO trial is particularly notable as it is being conducted by the renowned Maria Sk?odowska-Curie National Research Institute of Oncology (MSCNRIO) located in Poland, a center of excellence for STS research. The trial reached its target enrollment of 40 patients, signaling significant momentum in this clinical study that seeks to provide new hope for those suffering from STS.
Trial Details and Objectives
The primary goal of the EFTISARC-NEO trial is to evaluate the impact of combining efti with conventional radiotherapy and the immune checkpoint inhibitor KEYTRUDA®. This combination has the potential to enhance treatment efficacy for patients with previously resectable STS. The data emerging from this trial could set new standards in the neoadjuvant treatment landscape.
Preliminary Findings and Future Data Expectations
Preliminary data presented at a recent Oncology Society meeting highlighted substantial findings from an earlier phase of patient interactions in the trial. Among 21 patients assessed for the primary endpoint, results indicated a remarkable enhancement in tumor hyalinization and fibrosis following the treatment regimen. Specifically, there was a greater than three-fold increase in these parameters at surgery, compared to historical data where radiotherapy alone had showed a median increase of just 15%.
Safety and Side Effects
Moreover, the combination therapy has shown a favorable safety profile, with no reported cases of grade 3 or higher toxicities attributed to efti or pembrolizumab. This aspect is crucial in establishing an effective and tolerable treatment plan for patients, as safety is always a top priority in clinical trials.
Looking Ahead: What’s Next for Immutep?
With the completion of enrollment, all eyes are now on the anticipated data updates from the EFTISARC-NEO trial, expected to emerge in the near future. These updates will provide valuable insights not only about the efficacy of the treatment but also about its potential adoption in clinical practice.
About Immutep Limited
Founded with the vision to improve therapeutic options, Immutep is a clinical-stage biotechnology company at the forefront of developing exceptional immunotherapy solutions utilizing the LAG-3 pathway. The organization is devoted to transforming patient care in oncology and autoimmune disorders through their diverse portfolio targeting the immune response. They aim to maximize shareholder value while benefiting patient populations that are in critical need of new therapies.
Frequently Asked Questions
What is the purpose of the EFTISARC-NEO trial?
The trial aims to evaluate the safety and efficacy of eftilagimod alpha when used in combination with radiotherapy and KEYTRUDA® in patients with soft tissue sarcoma.
Who is conducting the EFTISARC-NEO trial?
The trial is being conducted by the Maria Sk?odowska-Curie National Research Institute of Oncology, a leading research center in Poland for soft tissue sarcoma.
How many patients have been enrolled in the trial?
The trial has reached its enrollment target of 40 patients, demonstrating significant participation and interest in exploring this innovative treatment approach.
What safety profile has been observed in initial data presentations?
The preliminary data indicated that the treatment combination was well-tolerated without any severe toxicities associated with efti or pembrolizumab.
When can we expect updates from the trial?
Data updates from the EFTISARC-NEO trial are anticipated in the coming years, likely revealing key findings about the treatment's effectiveness.
